Uncategorized

Phage Refinery has been chosen to compete in the BioFest Invest 2024 Pitch Competition on April 17, 2024. Founding CEO Bill Tolhurst will be presenting a brief overview of the company and where we’re headed to local and regional investors specifically focused on healthcare opportunities. If you’re there, be sure to look him up!

Phage Refinery is very excited to announce its PureFage™ Service, PureFage enables researchers and therapy development organizations to quickly and easily isolate and characterize phage for their target bacteria. Leveraging the technology and know-how from decades of world-class phage research, isolation can be performed on demand in days without the distraction and capital expense required

Phage Refinery has been selected to join the ARPA-H Customer Experience Hub (CX Hub). The CX Hub is part of ARPANET-H, and is a nationwide health innovation network of more than 300 of the leading healthcare entities spanning government and educational research, for-profit product and services firms, and clinical practitioners. The Advanced Research Projects Agency

Phage Refinery has been selected to join the San Antonio Venture Mentor Service (VMS-SA) as a mentored company. VMS-SA is a sister program of the Massachusetts Institute of Technology Venture Mentoring Service (MITVMS) and is supported by the University of Texas System. A joint collaboration between UTSA and UT Health SA, VMS-SA is managed by

On Sunday, January 21, 2024, CNN published an an informative article on the growing threat of Multi-Drug Resistant “superbug” bacterial infections, and the potential of phage therapy to combat this accelerating health crisis. The article includes some key observations from prominent phage researcher Dr. Dwayne Roach, professor at San Diego State University and member of

Phage Refinery has been accepted into the New Venture Incubator (NVI) at the University of Texas at San Antonio. The NVI program is focused on supporting the translation of research technology into commercialized products and services. The program is managed by Dr. Christine Burke, Director of the Office of Commercialization and Innovation, and will provide

Research results from Phage Refinery co-founders Dr Phil Serwer and Dr Jim Chambers was published September 27th, 2023 in Biophysica, an international, peer-reviewed, open access journal on applying the methods of physics, chemistry, and math to study biological systems. Along with colleagues Elena T. Wright and Barbara Hunter, their research demonstrates a safe means for preparing

Phage Refinery co-founders Dr. Phil Serwer and Dr. Jim Chambers had their recent research featured in a news article from the UT Health Science Center at San Antonio. Entitled “A naturally occurring alternative to antibiotics?“, it highlights their work in determining bacteriophage persistence as well as safely removing potential pathogens from phage samples. Their research